This table contains 2394 series, with data for years 1991 -1991 (not all combinations necessarily have data for all years). This table contains data described by the following dimensions (Not all combinations are available): Geography (1 items: Canada ...), Population group (19 items: Entire cohort; Income adequacy quintile 1 (lowest);Income adequacy quintile 3;Income adequacy quintile 2 ...), Age (14 items: At 25 years; At 30 years; At 35 years; At 40 years ...), Sex (3 items: Both sexes; Females; Males ...), Characteristics (3 items: Probability of survival; Low 95% confidence interval; life expectancy; High 95% confidence interval; life expectancy ...).

Annual data on death registrations by single year of age for the UK (1974 onwards) and England and Wales (1963 onwards).

Life expectancy at birth and at age 65, by sex, on a three-year average basis.

Number of deaths and mortality rates, by age group, sex, and place of residence, 1991 to most recent year.

Note: Starting April 27, 2023 updates change from daily to weekly. Summary The cumulative number of confirmed COVID-19 deaths among Maryland residents by age: 0-9; 10-19; 20-29; 30-39; 40-49; 50-59; 60-69; 70-79; 80+; Unknown. Description The MD COVID-19 - Confirmed Deaths by Age Distribution data layer is a collection of the statewide confirmed COVID-19 related deaths that have been reported each day by the Vital Statistics Administration by designated age ranges. A death is classified as confirmed if the person had a laboratory-confirmed positive COVID-19 test result. Some data on deaths may be unavailable due to the time lag between the death, typically reported by a hospital or other facility, and the submission of the complete death certificate. Probable deaths are available from the MD COVID-19 - Probable Deaths by Age Distribution data layer. Terms of Use The Spatial Data, and the information therein, (collectively the "Data") is provided "as is" without warranty of any kind, either expressed, implied, or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted, nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct, indirect, incidental, consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data, nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.

Number and percentage of deaths, by age group, sex, and place of residence, 1991 to most recent year.

This table contains mortality indicators by sex for Canada and all provinces except Prince Edward Island. These indicators are derived from three-year complete life tables. Mortality indicators derived from single-year life tables are also available (table 13-10-0837). For Prince Edward Island, Yukon, the Northwest Territories and Nunavut, mortality indicators derived from three-year abridged life tables are available (table 13-10-0140).

Provisional counts of the number of deaths registered in England and Wales, by age, sex, region and Index of Multiple Deprivation (IMD), in the latest weeks for which data are available.

This file contains COVID-19 death counts and rates by month and year of death, jurisdiction of residence (U.S., HHS Region) and demographic characteristics (sex, age, race and Hispanic origin, and age/race and Hispanic origin). United States death counts and rates include the 50 states, plus the District of Columbia. Deaths with confirmed or presumed COVID-19, coded to ICD–10 code U07.1. Number of deaths reported in this file are the total number of COVID-19 deaths received and coded as of the date of analysis and may not represent all deaths that occurred in that period. Counts of deaths occurring before or after the reporting period are not included in the file. Data during recent periods are incomplete because of the lag in time between when the death occurred and when the death certificate is completed, submitted to NCHS and processed for reporting purposes. This delay can range from 1 week to 8 weeks or more, depending on the jurisdiction and cause of death. Death counts should not be compared across jurisdictions. Data timeliness varies by state. Some states report deaths on a daily basis, while other states report deaths weekly or monthly. The ten (10) United States Department of Health and Human Services (HHS) regions include the following jurisdictions. Region 1: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont; Region 2: New Jersey, New York; Region 3: Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, West Virginia; Region 4: Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee; Region 5: Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin; Region 6: Arkansas, Louisiana, New Mexico, Oklahoma, Texas; Region 7: Iowa, Kansas, Missouri, Nebraska; Region 8: Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming; Region 9: Arizona, California, Hawaii, Nevada; Region 10: Alaska, Idaho, Oregon, Washington. Rates were calculated using the population estimates for 2021, which are estimated as of July 1, 2021 based on the Blended Base produced by the US Census Bureau in lieu of the April 1, 2020 decennial population count. The Blended Base consists of the blend of Vintage 2020 postcensal population estimates, 2020 Demographic Analysis Estimates, and 2020 Census PL 94-171 Redistricting File (see https://www2.census.gov/programs-surveys/popest/technical-documentation/methodology/2020-2021/methods-statement-v2021.pdf). Rate are based on deaths occurring in the specified week and are age-adjusted to the 2000 standard population using the direct method (see https://www.cdc.gov/nchs/data/nvsr/nvsr70/nvsr70-08-508.pdf). These rates differ from annual age-adjusted rates, typically presented in NCHS publications based on a full year of data and annualized weekly age-adjusted rates which have been adjusted to allow comparison with annual rates. Annualization rates presents deaths per year per 100,000 population that would be expected in a year if the observed period specific (weekly) rate prevailed for a full year. Sub-national death counts between 1-9 are suppressed in accordance with NCHS data confidentiality standards. Rates based on death counts less than 20 are suppressed in accordance with NCHS standards of reliability as specified in NCHS Data Presentation Standards for Proportions (available from: https://www.cdc.gov/nchs/data/series/sr_02/sr02_175.pdf.).

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

This dataset displays data from the 2005 Census of Japan. It displays data on Aged Single Persons throughout prefectures in Japan. This dataset specifically breaks up the age ranges into 6 different categories (65 and older, 65-69, 70-74, 75-79, 80-84 85 and older) for males, females, and both sexes. This data comes from Japan's Ministry of Internal Affairs and Communication's Statistics Bureau.

This file contains the following characteristics per case tested positive in the Netherlands: Date for statistics, Age group, Sex, Hospital admission, Death, Week of death, Province, Notifying GGD

The file is structured as follows: A record for every laboratory confirmed COVID-19 patient in the Netherlands, since the first COVID-19 report in the Netherlands on 27/02/2020 (Date for statistics may be earlier). The file is refreshed daily at 4 pm, based on the data as registered at 10 am that day in the national system for notifiable infectious diseases (Osiris AIZ).

Description of the variables

Date_file: Date and time when the data was published by RIVM

Date_statistics: Date for statistics; first day of illness, if unknown, date lab positive, if unknown, report date to GGD (format: yyyy-mm-dd)

Date_statistics_type: Type of date that was available for date for the variable "Date for statistics", where: DOO = Date of disease onset : First day of illness as reported by GGD. Please note: it is not always known whether this first day of illness was really Covid-19. DPL = Date of first Positive Labresult : Date of the (first) positive lab result. DON = Date of Notification : Date on which the notification was received by the GGD.

Agegroup: Age group at life; 0-9, 10-19, ..., 90+; at death <50, 50-59, 60-69, 70-79, 80-89, 90+, Unknown = Unknown

Sex: Sex; Unknown = Unknown, Male = Male, Female = Female

Province: Name of the province (based on the patient's whereabouts)

Hospital_admission: Hospital admission reported by the GGD. Unknown = Unknown, Yes = Yes, No = No From May 1, 2020, the indication of hospitalization will be related to Covid-19. If not, the value of this column is "No". Until June 1, only seriously ill people were tested, a large part of these people had already been or were admitted shortly afterwards. As a result, the hospital admissions registered by the GGD were more complete during the first wave. As of June 1, everyone can be tested and more people will be tested at an early stage. As a result, the GGD is not always informed, or with a delay, of a hospital admission. That is why RIVM has been actively naming the registered hospital admissions of the NICE Foundation (https://data.rivm.nl/geonetwork/srv/dut/catalog.search#/metadata/4f4ad069-8f24-4fe8-b2a7-533ef27a899f) since 6 October. RIVM uses these figures as a guideline because they provide a more complete picture than the hospital admissions reported by the GGD. Click here (https://www.rivm.nl/nieuws/nummer-nieuw-melde-covid-19-verzekeraars-stable) for more information about this.

Deceased: Death. Unknown = Unknown, Yes = Yes, No = No

Week of Death: Week of death. YYYYMM according to ISO week notation (start from Monday to Sunday)

Municipal_health_service: GGD that made the report.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Updated (Bivalent) Booster Status. Click 'More' for important dataset description and footnotes

Webpage: https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status

Dataset and data visualization details:

These data were posted and archived on May 30, 2023 and reflect cases among persons with a positive specimen collection date through April 22, 2023, and deaths among persons with a positive specimen collection date through April 1, 2023. These data will no longer be updated after May 2023.

Vaccination status: A person vaccinated with at least a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. A person vaccinated with a primary series and a monovalent booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and at least one additional dose of any monovalent FDA-authorized or approved COVID-19 vaccine on or after August 13, 2021. (Note: this definition does not distinguish between vaccine recipients who are immunocompromised and are receiving an additional dose versus those who are not immunocompromised and receiving a booster dose.) A person vaccinated with a primary series and an updated (bivalent) booster dose had SARS-CoV-2 RNA or antigen detected in a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and an additional dose of any bivalent FDA-authorized or approved vaccine COVID-19 vaccine on or after September 1, 2022. (Note: Doses with bivalent doses reported as first or second doses are classified as vaccinated with a bivalent booster dose.) People with primary series or a monovalent booster dose were combined in the “vaccinated without an updated booster” category.

Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Per the interim guidance of the Council of State and Territorial Epidemiologists (CSTE), this should include persons whose death certificate lists COVID-19 disease or SARS-CoV-2 as the underlying cause of death or as a significant condition contributing to death. Rates of COVID-19 deaths by vaccination status are primarily reported based on when the patient was tested for COVID-19. In select jurisdictions, deaths are included that are not laboratory confirmed and are reported based on alternative dates (i.e., onset date for most; or date of death or report date, where onset date is unavailable). Deaths usually occur up to 30 days after COVID-19 diagnosis.

Participating jurisdictions: Currently, these 24 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Colorado, District of Columbia, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (NY), North Carolina, Rhode Island, Tennessee, Texas, Utah, and West Virginia; 23 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 48% of the total U.S. population and all ten of the Health and Human Services Regions. This list will be updated as more jurisdictions participate.

Incidence rate estimates: Weekly age-specific incidence rates by vaccination status were calculated as the number of cases or deaths divided by the number of people vaccinated with a primary series, overall or with/without a booster dose (cumulative) or unvaccinated (obtained by subtracting the cumulative number of people vaccinated with at least a primary series and partially vaccinated people from the 2019 U.S. intercensal population estimates) and multiplied by 100,000. Overall incidence rates were age-standardized using the 2000 U.S. Census standard population. To estimate population counts for ages 6-12 months, half of the single-year population counts for ages <12 months were used. All rates are plotted by positive specimen collection date to reflect when incident infections occurred.

Continuity correction: A continuity correction has been applied to the denominators by capping the percent population coverage at 95%. To do this, we assumed that at least 5% of each age group would always be unvaccinated in each jurisdiction. Adding this correction ensures that there is always a reasonable denominator for the unvaccinated population that would prevent incidence and death rates from growing unrealistically large due to potential overestimates of vaccination coverage.

Incidence rate ratios (IRRs): IRRs for the past one month were calculated by dividing the average weekly incidence rates among unvaccinated people by that among people vaccinated without an updated (bivalent) booster dose) or vaccinated with an updated (bivalent) booster dose.

Archive: An archive of historic data, including April 3, 2021-September 24, 2022 and posted on October 21, 2022 is available on data.cdc.gov. The analysis by vaccination status (unvaccinated and at least a primary series) for 31 jurisdictions is posted here: https://data.cdc.gov/Public-Health-Surveillance/Rates-of-COVID-19-Cases-or-Deaths-by-Age-Group-and/3rge-nu2a. The analysis for one booster dose (unvaccinated, primary series only, and at least one booster dose) in 31 jurisdictions is posted here: https://data.cdc.gov/Public-Health-Surveillance/Rates-of-COVID-19-Cases-or-Deaths-by-Age-Group-and/d6p8-wqjm. The analysis for two booster doses (unvaccinated, primary series only, one booster dose, and at least two booster doses) in 28 jurisdictions is posted here: https://data.cdc.gov/Public-Health-Surveillance/Rates-of-COVID-19-Cases-or-Deaths-by-Age-Group-and/ukww-au2k.

References

Scobie HM, Johnson AG, Suthar AB, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1284–1290.

Johnson AG, Amin AB, Ali AR, et al. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021. MMWR Morb Mortal Wkly Rep 2022;71:132–138

Johnson AG, Linde L, Ali AR, et al. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination — 24 U.S. Jurisdictions, October 3, 2021–December 24, 2022. MMWR Morb Mortal Wkly Rep 2023;72:145–152

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases among people who received additional or booster doses were reported from 31 jurisdictions; 30 jurisdictions also reported data on deaths among people who received one or more additional or booster dose; 28 jurisdictions reported cases among people who received two or more additional or booster doses; and 26 jurisdictions reported deaths among people who received two or more additional or booster doses. This list will be updated as more jurisdictions participate. Incidence rate estimates: Weekly age-specific incidence rates by vaccination status were calculated as the number of cases or deaths divided by the number of people vaccinated with a primary series, overall or with/without a booster dose (cumulative) or unvaccinated (obtained by subtracting the cumulative number of people vaccinated with a primary series and partially vaccinated people from the 2019 U.S. intercensal population estimates) and multiplied by 100,000. Overall incidence rates were age-standardized using the 2000 U.S. Census standard population. To estimate population counts for ages 6 months through 1 year, half of the single-year population counts for ages 0 through 1 year were used. All rates are plotted by positive specimen collection date to reflect when incident infections occurred. For the primary series analysis, age-standardized rates include ages 12 years and older from April 4, 2021 through December 4, 2021, ages 5 years and older from December 5, 2021 through July 30, 2022 and ages 6 months and older from July 31, 2022 onwards. For the booster dose analysis, age-standardized rates include ages 18 years and older from September 19, 2021 through December 25, 2021, ages 12 years and older from December 26, 2021, and ages 5 years and older from June 5, 2022 onwards. Small numbers could contribute to less precision when calculating death rates among some groups. Continuity correction: A continuity correction has been applied to the denominators by capping the percent population coverage at 95%. To do this, we assumed that at least 5% of each age group would always be unvaccinated in each jurisdiction. Adding this correction ensures that there is always a reasonable denominator for the unvaccinated population that would prevent incidence and death rates from growing unrealistically large due to potential overestimates of vaccination coverage. Incidence rate ratios (IRRs): IRRs for the past one month were calculated by dividing the average weekly incidence rates among unvaccinated people by that among people vaccinated with a primary series either overall or with a booster dose. Publications: Scobie HM, Johnson AG, Suthar AB, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1284–1290. Johnson AG, Amin AB, Ali AR, et al. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021. MMWR Morb Mortal Wkly Rep 2022;71:132–138

Number of deaths and age-specific mortality rates for selected grouped causes, by age group and sex, 2000 to most recent year.

BackgroundThe association of cognitive function, its changes, and all-cause mortality has not reached a consensus, and the independence of the association between changes in cognitive function and mortality remains unclear. The purpose of this study was to evaluate the longitudinal association between baseline cognitive function and cognitive changes over 1 year with subsequent all-cause mortality among the older adults aged 60 and above.MethodsA prospective cohort study utilizing the Community Older Adults Health Survey data. Initiated in 2018, the study annually assessed all individuals aged 60+ in Dalang Town, Dongguan City. Cognitive function was assessed using the Chinese version of the Mini-Mental State Examination (MMSE). A total of 6,042 older adults individuals were included, and multivariate Cox proportional hazard models were used to examine cognitive function’s impact on mortality.ResultsParticipants’ median age was 70 years, with 39% men. Over a median 3.08-year follow-up, 525 died. Mortality risk increased by 6% per MMSE score decrease (adjusted HR = 1.06, 95%CI: 1.05–1.08). Compared to those with normal cognitive function at baseline, participants with mild cognitive impairment and moderate to severe cognitive impairment had significantly higher mortality risks (adjusted HR = 1.40, 95%CI: 1.07–1.82; HR = 2.49, 95%CI: 1.91–3.24, respectively). The risk of death was 5% higher for each one-point per year decrease in cognitive function change rate (HR = 1.05, 95%CI: 1.02–1.08). Compared with participants with stable cognitive function, those with rapid cognitive decline had a 79% increased risk of death (adjusted HR = 1.79, 95% CI: 1.11–2.87), with baseline cognitive function influencing this relationship significantly (P for interaction = 0.002).ConclusionBaseline cognitive impairment and rapid cognitive decline are associated with higher all-cause mortality risks in Chinese older adults. Baseline function influences the mortality impact of cognitive changes.

Estimated annual number of deaths by 5-year age groups and gender for Canada, provinces and territories.

Ivory Coast CI: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data was reported at 28.200 NA in 2016. This records a decrease from the previous number of 28.500 NA for 2015. Ivory Coast CI: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data is updated yearly, averaging 27.700 NA from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 28.500 NA in 2015 and a record low of 25.200 NA in 2000. Ivory Coast CI: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Ivory Coast – Table CI.World Bank.WDI: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

This dataset examines the number of unidentified persons reported to the Centers for Disease Control and Preventions (CDC) National Death Index (NDI), by State, from 1980 to 2004. This report also looks at the number of unidentified human remains reported to the Federal Bureau of Investigations (FBI) National Crime Information Center (NCIC) Unidentified Person File. It describes the characteristics by race and gender and the manner of death. Highlights include the following: Between 1980 and 2004, about 10,300 unidentified human remains were reported to the National Death Index (NDI). Almost three-quarters of unidentified persons were reported by 5 states; Arizona, California, Florida, New York, and Texas. Of the 2,900 National Crime Information Center records that contained data on the manner of death, 27% were ruled homicides; 12%, accidental deaths; 7%, natural causes; and 5%, suicides. The majority of unidentified persons were white (70%); blacks made up 15% of unidentified persons; and race could not be determined in 13% of the cases. For more information about this data go to: http://www.ojp.usdoj.gov/bjs/abstract/uhrus04.htm

Nigeria NG: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data was reported at 20.900 NA in 2016. This records an increase from the previous number of 20.800 NA for 2015. Nigeria NG: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data is updated yearly, averaging 21.000 NA from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 22.600 NA in 2000 and a record low of 20.800 NA in 2015. Nigeria NG: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Nigeria – Table NG.World Bank.WDI: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;